Drug Profile

Acoltremon - Alcon

Alternative Names: AR-15512; AVX 012; TRYPTYR; WS-12

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Instituto de Neurociencias de Alicante
Developer Alcon; AVX Pharma
Class Cyclohexanes; Ethers; Eye disorder therapies; Small molecules
Mechanism of Action TRPM8 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Registered Dry eyes

Most Recent Events

30 May 2025 Alcon plans to launch Acoltremon for Dry eyes in USA in the third quarter of 2025
28 May 2025 Registered for Dry eyes in USA (Ophthalmic) - First global approval
05 May 2025 FDA assigns PDUFA action date of 30/05/2025 for Acoltremon for Dry eyes

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com